• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, August 6, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Rates of long-term opiate use rises in Medicare cancer survivors each year after diagnosis

Bioengineer by Bioengineer
May 14, 2019
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

GALVESTON, Texas – Using Medicare data, new findings from The University of Texas Medical Branch at Galveston show for the first time that the rates of long term opiate therapy – a 90-day or more supply of opioids per year – for older cancer survivors remain high for at least five years in cancer survivors. The study also showed that cancer survivors diagnosed after 2004 had higher rates of opioid prescribing compared with those diagnosed earlier than 2004. These finding were recently published in The Journal of the American Geriatrics Society.

“Our study of 63,815 cancer survivors aged 66 years and older from the Texas Cancer Registry-Medicare linked database who had been diagnosed with cancer at least five years ago and had completed all cancer treatments found a persistently high rate of long-term opioid prescribing,” said senior author Mukaila Raji, UTMB professor and director, Division of Geriatrics Medicine. “The rate of extended opioid therapy for cancer patients diagnosed in 2008 was 7.1 percent before their cancer diagnosis but rose to 9.8 percent within a year of cancer treatments and to 13.3 percent five years after diagnosis.”

Opioid-based pain medications are a key part of the pain management plan for patients undergoing cancer treatment. About 28 percent of cancer survivors report moderate to severe pain even after curative anti-cancer treatment. The most common form of chronic pain in these people is neuropathic pain, which can last for months to years or even last throughout a lifetime. However, there have been growing concerns regarding long-term opioid therapy in older cancer survivors, a population at a high risk of opioid toxicities.

The researchers also found that cancer survivors diagnosed in 2004-2008 had higher rates of opioid prescribing than those diagnosed in 1995-1998 and 1999-2003.

“Taken together, the predictors of more extended opioid therapy were years since diagnosis, female gender, urban location, lung cancer diagnosis, disability as a reason for Medicare entitlement, Medicaid eligibility and a history of depression or drug abuse,” said Raji. “Our findings have the potential to guide public policy and clinical practice for safer and more effective pain treatments in elderly cancer survivors.”

Raji said that the findings also underscore the urgent need for a nationwide study of patterns and outcomes of opioid therapy and the effectiveness and safety of other pain treatment options in this rapidly growing population.

###

Other authors include UTMB’s Rahul Shah, Lin-Na Chou and Yong-Fang Kuo.

Media Contact
Donna Ramirez
[email protected]
http://dx.doi.org/10.1111/jgs.15945

Tags: AddictionAgingcancerMedicine/HealthPainPublic Health
Share13Tweet7Share2ShareShareShare1

Related Posts

Multiplex Assay Detects HIV-1, HBV, and STRs

Multiplex Assay Detects HIV-1, HBV, and STRs

August 6, 2025
GABA Best Detects Early Parkinson’s Changes with RBD

GABA Best Detects Early Parkinson’s Changes with RBD

August 6, 2025

New Scale Uncovers Why People Use Benzodiazepines

August 5, 2025

Neutrophil-Albumin Ratio Predicts Outcomes in Myocarditis

August 5, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Neuropsychiatric Risks Linked to COVID-19 Revealed

    73 shares
    Share 29 Tweet 18
  • Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    61 shares
    Share 24 Tweet 15
  • Predicting Colorectal Cancer Using Lifestyle Factors

    46 shares
    Share 18 Tweet 12
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Multiplex Assay Detects HIV-1, HBV, and STRs

GABA Best Detects Early Parkinson’s Changes with RBD

Flavor and Bioactive Potential of Roasted Rice Bran Oil

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.